ENGN vs. BCSF, CVII, TRIN, CION, AACT, FSNB, NETD, RRAC, CDRO, and IPXX
Should you be buying enGene stock or one of its competitors? The main competitors of enGene include Bain Capital Specialty Finance (BCSF), Churchill Capital Corp VII (CVII), Trinity Capital (TRIN), CION Investment (CION), Ares Acquisition Co. II (AACT), Fusion Acquisition Corp. II (FSNB), Nabors Energy Transition Corp. II (NETD), Rigel Resource Acquisition (RRAC), Codere Online Luxembourg (CDRO), and Inflection Point Acquisition Corp. II (IPXX). These companies are all part of the "holding & other investment offices" industry.
Bain Capital Specialty Finance (NYSE:BCSF) and enGene (NASDAQ:ENGN) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
In the previous week, enGene had 20 more articles in the media than Bain Capital Specialty Finance. MarketBeat recorded 26 mentions for enGene and 6 mentions for Bain Capital Specialty Finance. enGene's average media sentiment score of 1.15 beat Bain Capital Specialty Finance's score of -0.09 indicating that Bain Capital Specialty Finance is being referred to more favorably in the media.
Bain Capital Specialty Finance has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500.
Bain Capital Specialty Finance has higher revenue and earnings than enGene.
64.2% of enGene shares are held by institutional investors. 0.6% of Bain Capital Specialty Finance shares are held by company insiders. Comparatively, 13.7% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Bain Capital Specialty Finance received 50 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 43.18% of users gave Bain Capital Specialty Finance an outperform vote.
Bain Capital Specialty Finance currently has a consensus target price of $16.33, indicating a potential downside of 2.72%. enGene has a consensus target price of $34.40, indicating a potential upside of 291.35%. Given Bain Capital Specialty Finance's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than Bain Capital Specialty Finance.
Bain Capital Specialty Finance has a net margin of 43.42% compared to Bain Capital Specialty Finance's net margin of 0.00%. enGene's return on equity of 12.64% beat Bain Capital Specialty Finance's return on equity.
Summary
Bain Capital Specialty Finance beats enGene on 8 of the 15 factors compared between the two stocks.
Get enGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
